What is the primary purpose of this 8-K filing?

This 8-K filing's primary purpose is to report Amgen's unaudited financial results for the third quarter and the first nine months of 2012, along with its financial position as of September 30, 2012. A significant focus is on the company's use of non-GAAP financial measures to present performance and financial condition in a way that aids investor comparability.

Why does Amgen use non-GAAP financial measures?

Amgen uses non-GAAP financial measures to provide investors with supplemental information that they believe is useful for analyzing the company's ongoing operational profitability and financial condition. These measures exclude certain items that management believes are not indicative of the company's core, recurring business performance, such as specific transaction-related expenses, acquisition costs, and certain accounting adjustments, allowing for easier comparisons across different periods.

What are some of the key adjustments Amgen makes to its GAAP results?

Key adjustments include expenses related to the Boehringer Ingelheim manufacturing facility transaction, the impact of expensing stock options, acquisition-related costs, R&D cost-saving initiatives, amortization of acquired product technology rights, legal expenses, contingent consideration adjustments, and non-cash interest expense on convertible notes. The company also reports Free Cash Flow (FCF) as a non-GAAP liquidity measure.

Are the non-GAAP figures presented as a substitute for GAAP figures?

No, Amgen explicitly states that its non-GAAP financial measures are presented in addition to, not as a substitute for, or superior to, measures of financial performance prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). They are intended to provide supplementary information for additional analysis by investors.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) filed an 8-K on October 23, 2012, to report its unaudited financial results for the third quarter and the first nine months of 2012, alongside its financial position as of September 30, 2012. The filing primarily highlights the company's use of non-GAAP financial measures to provide supplemental insights into its performance and financial condition, aiming to facilitate clearer comparisons for investors by excluding certain items. The report details various adjustments made to GAAP figures, including expenses related to a manufacturing facility transaction with Boehringer Ingelheim, stock option expensing, acquisition-related costs, R&D cost-saving initiatives, amortization of product technology rights, legal expenses, contingent consideration, and non-cash interest expense on convertible notes. Amgen believes these adjustments offer a more meaningful view of ongoing operational profitability and financial health, particularly when comparing periods before and after specific significant events or accounting treatments.

Key Highlights

1Amgen reported its unaudited financial results for the three and nine months ended September 30, 2012, and its financial position as of September 30, 2012.
2The company utilized non-GAAP financial measures, explaining that these are supplemental to GAAP and are intended to provide better comparability across periods, especially concerning specific one-time or accounting-related expenses.
3Key adjustments to GAAP measures include costs associated with the Boehringer Ingelheim (BI) transaction, expensing of stock options, acquisition-related expenses, R&D cost-saving initiatives, and amortization of acquired product technology rights.
4The filing also details adjustments for legal expenses, contingent consideration, and non-cash interest expense related to convertible notes.
5Amgen provided non-GAAP adjusted operating expenses, operating income, provision for income taxes, net income, and earnings per share.
6Free Cash Flow (FCF), a non-GAAP measure calculated as cash flow from operations minus capital expenditures, was also reported for the three months ended September 30, 2011 and 2012, to offer a further measure of liquidity.
7The report includes detailed reconciliations between GAAP and non-GAAP figures, attached as part of the press release in Exhibit 99.1.

AMGEN INC 8-K Report, Financial Results (Oct 23, 2012)

Summary

Key Highlights

Frequently Asked Questions